NCT04221438 2026-03-12
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
Eastern Cooperative Oncology Group
Phase 2 Terminated
Clinical Trials
12 trialsNCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT04543188 2025-10-23
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
Phase 1 Terminated
NCT03898908 2025-05-21
EBRAIN-MEL
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT03864042 2024-09-27
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT05810740 2024-09-19
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
Pierre Fabre Medicament
Phase 1 Completed
NCT04655157 2024-05-23
QUAD01
University of Pittsburgh
Phase 1/2 Terminated
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT01320085 2024-01-24
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Pfizer
Phase 2 Completed
NCT03911869 2023-05-31
POLARIS
Pfizer
Phase 2 Terminated
NCT01763164 2021-03-22
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Pfizer
Phase 3 Completed
NCT01801358 2020-09-16
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Array BioPharma
Phase 1/2 Terminated